- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Strauss moves to Access Radiology
Strauss moves to Access RadiologyTeleradiology and miniPACS firm Access Radiology has signed on Fuji Medical Systems USA veteran John Strauss to fill a newly created position as vice president of marketing. Access vice president of sales and
Strauss moves to Access Radiology
Teleradiology and miniPACS firm Access Radiology has signed on Fuji Medical Systems USA veteran John Strauss to fill a newly created position as vice president of marketing. Access vice president of sales and marketing Dave Mahoney will now serve as vice president of sales for the Lexington, MA-based company.
Strauss, who was with Stamford, CT-based Fuji for the past eight years, has developed a reputation as one of computed radiography's most knowledgeable proponents. In his position as director of marketing for imaging and information networks, he oversaw Fuji's development of its Synapse PACS program, as well as its CR operations. His first day at Access was May 17.
- Search again
- Homepage
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
